benzyl 4-(aminomethyl)-4-hydroxypiperidine-1-carboxylate | 85151-16-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl 4-(aminomethyl)-4-hydroxypiperidine-1-carboxylate
• 英文别名: 4-aminomethyl-1-CBZ-piperidin-4-ol
• CAS: 85151-16-2
• 化学式: C₁₄H₂₀N₂O₃
• 分子量: 264.324
• InChiKey: LWIUVSBTWBNGLT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  75.8
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  benzyl 4-(aminomethyl)-4-hydroxypiperidine-1-carboxylate 在 palladium 10% on activated carbon 、 氢气 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 20.17h， 生成 tert-butyl N-[[1-(5-bromo-3-fluoro-2-pyridyl)-4-hydroxy-4-piperidyl]methyl]carbamate
  参考文献：
  名称：

  [EN] COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS
  [FR] COMPOSÉS POUR LE CIBLAGE DE LA DÉGRADATION DE PROTÉINES IRAK4

  摘要：

  This disclosure relates to compounds of Formula (A): IRAK—L—DSM (A), or a pharmaceutically acceptable salt thereof, wherein DSM is a degradation signaling moiety that is covalently attached to the linker L, L is a linker that covalently attaches IRAK to DSM; and IRAK is an IRAK4 binding moiety represented by Formula (I) that is covalently attached to linker L; in which all of the variables are as defined in the application. Compounds or pharmaceutically acceptable salts thereof as described herein are capable of activating the selective ubiqitination of IRAK4 proteins via the ubiquitin-proteasome pathways (UPP) and cause degradation of IRAK4 proteins. The present disclosure also provides methods of treating disorders responsive to modulation of IRAK4 activity and/or degradation of IRAK4 with at least one compound described herein.

  公开号：

  WO2023283610A1
• 作为产物：
  描述：

  1-噁-6-氮杂螺[2.5]辛烷-6-羧酸苄酯 在 氨 作用下， 反应 20.0h， 以100%的产率得到benzyl 4-(aminomethyl)-4-hydroxypiperidine-1-carboxylate
  参考文献：
  名称：

  Antihypertensive 9-substituted 1-0xa-4,9-diazaspiro[5.5]undecan-3-ones

  摘要：

  Forty-one 9-substituted 1-oxa-4,9-diazaspiro[5.5]undecan-3-ones were prepared for antihypertensive screening in the spontaneously hypertensive rat (SHR). For the 9-(2-indol-3-ylethyl) series, the parent compound, 9-(2-indol-3-ylethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one (21), was the most potent antihypertensive agent. Substitution of lower alkyl groups on the spirolactam ring gave compounds close in activity to 21, while substitution with large alkyl or aryl groups led to a significant decrease in activity. Ring-opened analogues of 21 that contained the same functionality were markedly less active. Several 1-oxa-4,9-diazaspiro[5.5]undecan-3-ones substituted at the 9 position with 1,4-benzodioxan-2-ylmethyl, 1,4-benzodioxan-2-ylhydroxyethyl, and 2-phenylethyl groups also demonstrated significant activity. Compound 21 was chosen for a detailed pharmacological evaluation. Its antihypertensive activity appears to be predominantly due to peripheral alpha 1-adrenoceptor blockade.

  DOI：

  10.1021/jm00360a013

文献信息

• N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists
  申请人：——

  公开号：US20020165241A1

  公开（公告）日：2002-11-07

  Compounds represented by Formula (I): 1 or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain.

  由化学式（I）表示的化合物及其药学上可接受的盐，可作为NMDA NR2B拮抗剂，用于缓解疼痛。
• Nr2b receptor antagonists for the treatment or prevention of migraines
  申请人：——

  公开号：US20040204341A1

  公开（公告）日：2004-10-14

  The present invention encompasses a method for treating or preventing migraines in a mammalian patient in need of such treatment or prevention comprising administering to said patient an NR2B receptor antagonist in an amount that is effective to treat or prevent migraines. The invention also encompasses the combination of an NR2B antagonist with a cyclooxygenase-2 selective inhibitor, a calcitonin gene-related peptide receptor (CGRP) ligand, a leukotriene receptor antagonist or a 5HT 1B/1D agonist for the treatment or prevention of migraines.

  本发明涵盖了一种治疗或预防哺乳动物患者偏头痛的方法，包括向该患者施用有效治疗或预防偏头痛的NR2B受体拮抗剂。该发明还涵盖了将NR2B拮抗剂与环氧合酶2选择性抑制剂、降钙素基因相关肽受体（CGRP）配体、白三烯受体拮抗剂或5HT1B/1D激动剂结合使用，用于治疗或预防偏头痛。
• N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
  申请人：——

  公开号：US20040209889A1

  公开（公告）日：2004-10-21

  Compounds represented by Formula (I): (I)or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain. 1

  式(I)所代表的化合物或其药学上可接受的盐，作为NMDA NR2B拮抗剂，对缓解疼痛有效。
• 9-(2-(3-Indolyl)ethyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones
  申请人：SYNTEX (U.S.A.) INC.

  公开号：EP0061333A1

  公开（公告）日：1982-09-29

  Compounds useful in the prevention and/or treatment of hypertension, congestive heart failure, arrhythmia, migraine, vasospastic disorders, and asthma are represented by the formula wherein: R, R1, R2, R3, and R4 are independently hydrogen or lower alkyl of one to four carbon atoms; and R5 and R6 are independently hydrogen, lower alkyl of one to four carbon atoms or lower alkoxy of one to four carbon atoms; and the pharmaceutically acceptable acid addition salts thereof.

  用于预防和/或治疗高血压、充血性心力衰竭、心律失常、偏头痛、血管痉挛性疾病和哮喘的化合物由式表示 其中 R、R1、R2、R3 和 R4 独立地为氢或一至四个碳原子的低级烷基；以及 R5 和 R6 独立地是氢、一至四个碳原子的低级烷基或一至四个碳原子的低级烷氧基；以及 其药学上可接受的酸加成盐。
• N-SUBSTITUTED NONARYL-HETEROCYCLIC NMDA/NR2B ANTAGONISTS
  申请人：Merck & Co., Inc.

  公开号：EP1379520B1

  公开（公告）日：2006-04-26